Our research work includes evaluation of local administration of drugs in arteriosclerosis and in prevention of restenosis after angioplasty procedures, investigation for preventing myocardial reperfusion injury after angioplasty, as well as methods for myocardial regeneration and vessel regeneration after cardiac infarction
We develop and test novel methods of valve reparation and percutaneous heart valve implantation, new intravascular stents including biodegradable stents and novel techniques of interventional treatment of hypertension. We also try to limit central nervous system damages caused by ischemia due to application of stem cells.
Over the last several years of CCRD AHP operation, we managed to achieve great success. Projects conducted in CCRD allowed for introduction to the clinical practise, among other things:
|first Polish coronary stent made of stainless steel 316L “Chopin”|
|coronary stent made of cobalt-chromium alloy “KOS”|
|first Polish anti-proliferative biodegradable polymer-coated paclitaxel-eluting stent (Luc-Chopin2)|
|“Shellak” coating used on stent and balloon surfaces|
|coronary stent “Alex” eluting sirolimus|
|antiproliferative drug-coated balloons|
In 2006, CCRD AHP scientists were awarded by the “Working Group of Interventional Cardiology” for a study “Biodegradable polymer coated, paclitaxel eluting stents in the porcine coronary arteries”. In April 2014, during an International Conference on Interventional Cardiology in Seoul, our General Director was awarded the prize “TCTAP Best Presenter” for his presentation of an innovative program of hybrid procedures implemented by CCRD AHP.